CLINICAL_TRIALS
trial_result
· 2020-11-30
Clinical Trial Update: Efficacy and Safety of HIP1601 Capsule [Phase 3]
Summary
Phase 3 study update on HIP1601 Capsule for erosive gastroesophageal reflux disease.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Hanmi Pharmaceutical Company Limited | Conditions: Erosive Gastroesophageal Reflux Disease | Phase 3 | Status: COMPLETED